Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific introduces Precision pain reliever

This article was originally published in The Gray Sheet

Executive Summary

Spinal cord stimulation system for the treatment of chronic pain in the limbs, trunk and back will undergo a full European launch in 2006, with initial roll-out to begin this year. The firm received a CE mark for the device Sept. 13. Boston Scientific acquired the PMA-approved device with its $740 mil. purchase of Advanced Bionics in June 2004 and launched it in the U.S. in March. The European version includes a longer-life battery - not yet approved in the U.S. - that can last up to 25 years. Boston Scientific is developing several additional indications for Precision, including migraine headache (1"The Gray Sheet" Feb. 7, 2005, p. 4)...

You may also be interested in...

Advanced Bionics Spinal Cord Stimulation Launch Continues With Precision

Boston Scientific's Advanced Bionics unit expects to have a 100-person sales force in place by the end of the third quarter to market its Precision spinal cord stimulation (SCS) system for chronic pain and future indications, including migraine headache

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts